MONICA LOVINS: Open Payments
NPI 1861732331 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,098 in 134 payments from 19 companies in 2025. Trend: 2023 $2,780 · 2024 $2,969 · 2025 $7,098
Food & beverage: $3,357Consulting: $2,640Travel & lodging: $1,041Education: $60
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 28 | $4,447 |
| ABBVIE INC. | 26 | $545 |
| Madrigal Pharmaceuticals | 10 | $385 |
| PFIZER INC. | 11 | $256 |
| Janssen Biotech, Inc. | 11 | $231 |
| Ardelyx, Inc. | 10 | $205 |
| GENZYME CORPORATION | 3 | $162 |
| Novo Nordisk Inc | 2 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $124 |
| Actelion Pharmaceuticals US, Inc. | 1 | $120 |
Products named: Livdelzi, REZDIFFRA, SKYRIZI, TREMFYA, DUPIXENT, IBSRELA, VELSIPITY, CREON.
Industry payments across MD — which companies pay providers there.
